Novo Nordisk A/S
Satış
Güncellendi

Novo Nordis Short

614

Shorting Novo Nordisk may be considered due to potential overvaluation, rising competition in diabetes and obesity markets, supply chain challenges, and risks from patent expirations. Regulatory hurdles, slower demand in key regions, and macroeconomic factors like healthcare budgets and inflation could further impact growth. However, thorough analysis is essential, as shorting carries high risk.
Not
at the neckline, could have a bit of oscillation, but once break down $120, heading to the target $100.
Not
Neckline broke, any small fundamental issue would incur the acceleration to the target
Not
will close half of my put position when it hits below $110 prior to the earning, that would give the trade a 75% profit
İşlem kapandı: hedefe ulaştı
Closed my position.

Feragatname

Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.